The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low
single-dose primaquine for gametocidal activity against P.falciparum among adult
glucose-6-phosphate dehydrogenase (G6PD)-normal malaria patients.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Bill and Melinda Gates Foundation Mahidol Oxford Tropical Medicine Research Unit Malaria Research and Training Center, Bamako, Mali Shoklo Malaria Research Unit Shoklo Malaria Research, Tak, Thailand Wellcome Trust